Quick Answer
Candel Therapeutics, Inc. reported Long-Term Debt of $560.0 thousand for fiscal year 2021.
Candel Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2021 | $560.0K | +15.9% |
| 2020 | $483.0K | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2021 | $541.0K | — | +3.8% |
| June 30, 2021 | $521.0K | — | +7.9% |
| December 31, 2020 | $483.0K | — | — |
- Candel Therapeutics, Inc. showed an increase of +15.9% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2021 period, Candel Therapeutics, Inc.’s long-term debt has grown by 15.9% (from $483.0 thousand to $560.0 thousand).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 29, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: